CY1116361T1 - Ετεροαρωματικα αρυλο τριαζολικα παραγωγα ως αναστολεις pde10a ενζυμου - Google Patents
Ετεροαρωματικα αρυλο τριαζολικα παραγωγα ως αναστολεις pde10a ενζυμουInfo
- Publication number
- CY1116361T1 CY1116361T1 CY20141100012T CY141100012T CY1116361T1 CY 1116361 T1 CY1116361 T1 CY 1116361T1 CY 20141100012 T CY20141100012 T CY 20141100012T CY 141100012 T CY141100012 T CY 141100012T CY 1116361 T1 CY1116361 T1 CY 1116361T1
- Authority
- CY
- Cyprus
- Prior art keywords
- formula
- subject
- compound
- effective amount
- therapeutically effective
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Η εφεύρεση αυτή εστιάζεται σε ενώσεις (Τύπος 1), οι οποίες είναι αναστολείς του PDE10A ενζύμου. Η εφεύρεση παρέχει μία φαρμακευτική σύνθεση η οποία περιλαμβάνει μία θεραπευτικώς αποτελεσματική ποσότητα μιας ένωσης της εφεύρεσης και έναν φαρμακευτικώς αποδεκτό φορέα. Η παρούσα εφεύρεση επίσης παρέχει διαδικασίες για την παρασκευή των ενώσεων του τύπου (I). Η παρούσα εφεύρεση περαιτέρω παρέχει μία μέθοδο αγωγής ενός υποκειμένου το οποίο πάσχει από μια νευροεκφυλιστική διαταραχή η οποία περιλαμβάνει τη χορήγηση στο υποκείμενο μιας θεραπευτικώς αποτελεσματικής ποσότητας μιας ένωσης του τύπου (I). Η παρούσα εφεύρεση επίσης παρέχει μία μέθοδο αγωγής ενός υποκειμένου το οποίο πάσχει από έναν εθισμό σε φάρμακο η οποία περιλαμβάνει τη χορήγηση στο υποκείμενο μιας θεραπευτικώς αποτελεσματικής ποσότητας μιας ένωσης του τύπου (I). Η παρούσα εφεύρεση περαιτέρω παρέχει μία μέθοδο αγωγής ενός υποκειμένου το οποίο πάσχει από μια ψυχιατρική διαταραχή η οποία περιλαμβάνει τη χορήγηση στο υποκείμενο μιας θεραπευτικώς αποτελεσματικής ποσότητας μιας ένωσης του τύπου (I).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28732109P | 2009-12-17 | 2009-12-17 | |
DKPA200901340 | 2009-12-17 | ||
EP10797991.6A EP2513106B1 (en) | 2009-12-17 | 2010-12-15 | Heteroaromatic aryl triazole derivatives as pde10a enzyme inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1116361T1 true CY1116361T1 (el) | 2017-02-08 |
Family
ID=44246811
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20141100012T CY1116361T1 (el) | 2009-12-17 | 2014-01-07 | Ετεροαρωματικα αρυλο τριαζολικα παραγωγα ως αναστολεις pde10a ενζυμου |
Country Status (36)
Country | Link |
---|---|
US (2) | US8501795B2 (el) |
EP (1) | EP2513106B1 (el) |
JP (1) | JP6035149B2 (el) |
KR (1) | KR101779629B1 (el) |
CN (1) | CN102753550B (el) |
AR (1) | AR079496A1 (el) |
AU (1) | AU2010333438B2 (el) |
BR (1) | BR112012014486A2 (el) |
CA (1) | CA2783728C (el) |
CO (1) | CO6602117A2 (el) |
CR (1) | CR20120318A (el) |
CY (1) | CY1116361T1 (el) |
DK (1) | DK2513106T3 (el) |
DO (1) | DOP2012000169A (el) |
EA (1) | EA021606B1 (el) |
ES (1) | ES2442179T3 (el) |
GE (1) | GEP20146201B (el) |
GT (1) | GT201200193A (el) |
HK (1) | HK1177745A1 (el) |
HR (1) | HRP20131210T1 (el) |
IL (1) | IL220328A (el) |
MA (1) | MA33923B1 (el) |
MX (1) | MX2012006715A (el) |
MY (1) | MY156520A (el) |
NZ (1) | NZ600365A (el) |
PL (1) | PL2513106T3 (el) |
PT (1) | PT2513106E (el) |
RS (1) | RS53101B (el) |
SG (1) | SG181672A1 (el) |
SI (1) | SI2513106T1 (el) |
SM (1) | SMT201400009B (el) |
TN (1) | TN2012000278A1 (el) |
TW (1) | TWI487705B (el) |
UA (1) | UA107950C2 (el) |
WO (1) | WO2011072697A1 (el) |
ZA (1) | ZA201204420B (el) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI485151B (zh) | 2009-12-17 | 2015-05-21 | Lundbeck & Co As H | 作為pde10a酵素抑制劑之雜芳香族苯基咪唑衍生物 |
TWI481607B (zh) | 2009-12-17 | 2015-04-21 | Lundbeck & Co As H | 作為pde10a酵素抑制劑的2-芳基咪唑衍生物 |
TWI487705B (zh) * | 2009-12-17 | 2015-06-11 | Lundbeck & Co As H | 作為pde10a酵素抑制劑之雜芳香族芳基三唑衍生物 |
EP3210984B1 (en) | 2011-01-11 | 2019-06-19 | Sunovion Pharmaceuticals Inc. | Heteroaryl compounds and methods of use thereof |
RU2013142364A (ru) | 2011-02-18 | 2015-03-27 | Аллерган, Инк. | Замещенные производные 6,7-диалкокси-3-изохинолинола в качестве ингибиторов фосфодиэстеразы 10 (фдэ10а) |
SG11201400759RA (en) * | 2011-09-19 | 2014-07-30 | Hoffmann La Roche | Triazolopyridine compounds as pde10a inhibitors |
WO2013127817A1 (en) | 2012-02-27 | 2013-09-06 | H. Lundbeck A/S | Imidazole derivatives as pde10a enzyme inhibitors |
AU2013269800A1 (en) * | 2012-05-30 | 2014-10-09 | F. Hoffmann-La Roche Ag | Triazolo compounds as PDE10 inhibitors |
SG11201408178TA (en) * | 2012-06-19 | 2015-01-29 | Sunovion Pharmaceuticals Inc | Heteroaryl compounds and methods of use thereof |
WO2014071044A1 (en) | 2012-11-01 | 2014-05-08 | Allergan, Inc. | Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a) |
EP2919781B1 (en) * | 2012-11-15 | 2017-06-28 | Merck Sharp & Dohme Corp. | Cyclobutyl benzimidazoles as pde10 inhibitors |
CA2930293A1 (en) * | 2013-11-28 | 2015-06-04 | F. Hoffmann-La Roche Ag | Imidazole derivatives |
US9200016B2 (en) | 2013-12-05 | 2015-12-01 | Allergan, Inc. | Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) |
CN114671874B (zh) * | 2021-08-30 | 2024-02-02 | 济南爱思医药科技有限公司 | 一种具有抗肿瘤活性的茶碱乙酸衍生物及其制备方法与应用 |
WO2023064458A1 (en) * | 2021-10-13 | 2023-04-20 | Yale University | Selective jak2 inhibitors and methods of use |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1462521A (en) | 1974-02-11 | 1977-01-26 | Wyeth John & Brother Ltd | Triazole derivatives |
GB8307865D0 (en) | 1983-03-22 | 1983-04-27 | Fujisawa Pharmaceutical Co | Benzimidazole derivatives |
US5571775A (en) | 1994-07-11 | 1996-11-05 | Dowelanco | N-aryl[1,2,4]triazolo[1,5-a]pyridine-2-sulfonamide herbicides |
US6699853B2 (en) | 1997-06-16 | 2004-03-02 | Hoechst Schering Agrevo Gmbh | 4-haloalkyl-3-heterocyclylpyridines, 4-haloalkyl-5-heterocyclyl-pyrimidines and 4-trifluoromethyl-3-oxadiazolylpyridines, processes for their preparation, compositions comprising them, and their use as pesticides |
SE9802937D0 (sv) | 1998-09-01 | 1998-09-01 | Astra Pharma Prod | Novel compounds |
IL149106A0 (en) | 2001-04-20 | 2002-11-10 | Pfizer Prod Inc | Therapeutic use of selective pde10 inhibitors |
US20030032579A1 (en) | 2001-04-20 | 2003-02-13 | Pfizer Inc. | Therapeutic use of selective PDE10 inhibitors |
FR2824065A1 (fr) | 2001-04-26 | 2002-10-31 | Neuro3D | Composes inhibiteurs des phosphodiesterases des nucleotides cycliques, preparation et utilisations |
ES2315546T3 (es) | 2002-10-30 | 2009-04-01 | Via Pharmaceuticals, Inc. | Inhibidores delas fosfodiesterasas de los nucleotidos ciclicos, que presentan una estructura de benzodiazepina, y su uso en terapia. |
CA2530114A1 (en) | 2003-06-30 | 2005-01-13 | Altana Pharma Ag | Pyrrolo-dihydroisoquinoline derivatives as pde10 inhibitors |
BRPI0411897A (pt) | 2003-06-30 | 2006-08-29 | Altana Pharma Ag | pirroldihidroisoquinolinas como inibidores de pde10 |
JP2007508241A (ja) | 2003-07-31 | 2007-04-05 | バイエル・フアーマシユーチカルズ・コーポレーシヨン | Pde10a阻害剤を用いる糖尿病および関連障害の処置方法 |
BRPI0507839A (pt) | 2004-02-18 | 2007-05-08 | Pfizer Prod Inc | derivados tetraidroisoquinolinil de quinazolina e isoquinolina |
FR2870539B1 (fr) | 2004-05-19 | 2006-08-04 | Greenpharma Sa Sa | Nouvelles methodes et medicaments |
BRPI0511854A (pt) * | 2004-06-07 | 2008-01-15 | Pfizer Prod Inc | inibição de fosfodiestearase 10 como tratamento para condições relacionados com a obesidade e relacionadas a sìndrome metabólica |
US20060019975A1 (en) | 2004-07-23 | 2006-01-26 | Pfizer Inc | Novel piperidyl derivatives of quinazoline and isoquinoline |
WO2006028957A1 (en) | 2004-09-03 | 2006-03-16 | Memory Pharmaceuticals Corporation | 4-substituted 4, 6-dialkoxy-cinnoline derivatives as phospodiesterase 10 inhibitors for the treatment of psychiatric or neurological syndroms |
NL2000397C2 (nl) * | 2006-01-05 | 2007-10-30 | Pfizer Prod Inc | Bicyclische heteroarylverbindingen als PDE10 inhibitoren. |
US20080090834A1 (en) * | 2006-07-06 | 2008-04-17 | Pfizer Inc | Selective azole pde10a inhibitor compounds |
WO2008006372A1 (en) * | 2006-07-10 | 2008-01-17 | H. Lundbeck A/S | (3-aryl-piperazin-1-yl), (2-aryl-morpholin-4-yl) and (2-aryl- thiomorpholin-4-yl) derivatives of 6,7-dialkoxyquinazoline, 6,7- dialkoxyphtalazine and 6,7-dialkoxyisoquinoline |
JP2010533715A (ja) | 2007-07-17 | 2010-10-28 | アムジエン・インコーポレーテツド | 複素環系pkb調節剤 |
GB0800411D0 (en) | 2008-01-10 | 2008-02-20 | Glaxo Group Ltd | Novel compounds |
TWI481607B (zh) | 2009-12-17 | 2015-04-21 | Lundbeck & Co As H | 作為pde10a酵素抑制劑的2-芳基咪唑衍生物 |
TWI485151B (zh) | 2009-12-17 | 2015-05-21 | Lundbeck & Co As H | 作為pde10a酵素抑制劑之雜芳香族苯基咪唑衍生物 |
TWI487705B (zh) * | 2009-12-17 | 2015-06-11 | Lundbeck & Co As H | 作為pde10a酵素抑制劑之雜芳香族芳基三唑衍生物 |
NZ705135A (en) * | 2010-05-26 | 2017-10-27 | Sunovion Pharmaceuticals Inc | Heteroaryl compounds and methods of use thereof |
-
2010
- 2010-12-13 TW TW099143441A patent/TWI487705B/zh not_active IP Right Cessation
- 2010-12-15 MA MA35064A patent/MA33923B1/fr unknown
- 2010-12-15 SG SG2012043493A patent/SG181672A1/en unknown
- 2010-12-15 US US13/515,351 patent/US8501795B2/en not_active Expired - Fee Related
- 2010-12-15 DK DK10797991.6T patent/DK2513106T3/da active
- 2010-12-15 GE GEAP201012784A patent/GEP20146201B/en unknown
- 2010-12-15 PL PL10797991T patent/PL2513106T3/pl unknown
- 2010-12-15 PT PT107979916T patent/PT2513106E/pt unknown
- 2010-12-15 MX MX2012006715A patent/MX2012006715A/es active IP Right Grant
- 2010-12-15 SI SI201030474T patent/SI2513106T1/sl unknown
- 2010-12-15 UA UAA201207980A patent/UA107950C2/uk unknown
- 2010-12-15 MY MYPI2012002595A patent/MY156520A/en unknown
- 2010-12-15 CN CN201080064069.0A patent/CN102753550B/zh not_active Expired - Fee Related
- 2010-12-15 KR KR1020127015379A patent/KR101779629B1/ko active IP Right Grant
- 2010-12-15 RS RS20130588A patent/RS53101B/en unknown
- 2010-12-15 ES ES10797991.6T patent/ES2442179T3/es active Active
- 2010-12-15 WO PCT/DK2010/050344 patent/WO2011072697A1/en active Application Filing
- 2010-12-15 JP JP2012543477A patent/JP6035149B2/ja not_active Expired - Fee Related
- 2010-12-15 NZ NZ600365A patent/NZ600365A/xx not_active IP Right Cessation
- 2010-12-15 EA EA201290517A patent/EA021606B1/ru not_active IP Right Cessation
- 2010-12-15 EP EP10797991.6A patent/EP2513106B1/en active Active
- 2010-12-15 CA CA2783728A patent/CA2783728C/en not_active Expired - Fee Related
- 2010-12-15 AU AU2010333438A patent/AU2010333438B2/en not_active Ceased
- 2010-12-15 BR BR112012014486A patent/BR112012014486A2/pt not_active Application Discontinuation
- 2010-12-16 AR ARP100104669A patent/AR079496A1/es unknown
-
2012
- 2012-05-31 TN TNP2012000278A patent/TN2012000278A1/en unknown
- 2012-06-12 CR CR20120318A patent/CR20120318A/es unknown
- 2012-06-12 IL IL220328A patent/IL220328A/en not_active IP Right Cessation
- 2012-06-13 GT GT201200193A patent/GT201200193A/es unknown
- 2012-06-15 DO DO2012000169A patent/DOP2012000169A/es unknown
- 2012-06-15 CO CO12101114A patent/CO6602117A2/es active IP Right Grant
- 2012-06-15 ZA ZA2012/04420A patent/ZA201204420B/en unknown
-
2013
- 2013-04-23 HK HK13104921.1A patent/HK1177745A1/xx not_active IP Right Cessation
- 2013-06-20 US US13/922,371 patent/US8785653B2/en not_active Expired - Fee Related
- 2013-12-19 HR HRP20131210AT patent/HRP20131210T1/hr unknown
-
2014
- 2014-01-07 CY CY20141100012T patent/CY1116361T1/el unknown
- 2014-01-22 SM SM201400009T patent/SMT201400009B/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1116361T1 (el) | Ετεροαρωματικα αρυλο τριαζολικα παραγωγα ως αναστολεις pde10a ενζυμου | |
CY1115278T1 (el) | Παραγωγα 2-αρυλιμιδαζολης ως αναστολεις του ενζυμου ρdε10α | |
CY1115843T1 (el) | Ετεροαρωματικες ενωσεις φαινυλιμιδαζολιου ως αναστολεις ενζυμου pde10a | |
CY1115001T1 (el) | Νεα παραγωγα φαινυλιμιδαζολιου ως αναστολεις ενζυμου pde10a | |
IN2015DN02829A (el) | ||
CY1120881T1 (el) | Ανταγωνιστες υποδοχεα 5-ητ3 | |
PH12014501695B1 (en) | Pde9 inhibitors with imidazo triazinone backbone | |
UA102693C2 (ru) | Производные фенилимидазола как ингибиторы фермента pde10a | |
EA200702048A1 (ru) | Фармакокинетически улучшенные соединения | |
EA201170872A1 (ru) | Ингибиторы протеинкиназы | |
UA112065C2 (uk) | Похідні імідазолу як інгібітори ферменту pde10a | |
EP2416795A4 (en) | COGNITIVE DECLINE INHIBITORS | |
CY1116689T1 (el) | Παραγωγα ιμιδαζολης ως αναστολεις του ενζυμου pde10a | |
MX336915B (es) | Derivados de imidazol como inhibidores de la enzima pde10a. |